Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

for
Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT00451022

Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

for
HER2-negative Breast Cancer,
Location: Jacksonville FL
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT06388122

Recruiting

ORB-021 In Patients With Advanced Solid Tumors

for
Advanced Solid Tumors Cancer
Location: Houston TX, Scottsdale AZ
Sponsor: Orionis Biosciences Inc

Sex: All

Age: 18+

Code: NCT06607939

Phase 1, Recruiting

Safety and Effectiveness of Sculptra 011611 for Improvement in Appearance of Gluteal Skin Irregularities

for
Gluteal Skin Irregularities
Location: Westmount, Toronto, Woodbridge, Burlington, Vancouver
Sponsor: Galderma R&D

Sex: Female

Age: 18+

Code: NCT07324564

Recruiting

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

for
Neoplasms
Location: New Hyde Park NY, Toronto, Philadelphia PA, Ottawa,
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT07277270

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

for
Solid Tumor Malignancies
Location: Westwood KS
Sponsor: University of Kansas Medical Center

Sex: All

Age: 18+

Code: NCT07174453

Phase 3, Recruiting

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

for
Metastatic Malignant Solid Neoplasm,
Location: Boston MA, Deerfield Beach FL, Coral Gables FL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04585958

Phase 1, Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

for
Solid Tumor, Adult, Refractory Cancer,
Location: Boston MA, New Haven CT, New York NY, Fairfax VA,
Sponsor: GV20 Therapeutics

Sex: All

Age: 18+

Code: NCT05669430

Phase 1, Phase 2, Recruiting

Definitive Radiation Therapy for Inoperable Breast Cancer

for
Breast Cancer, Breast Adenocarcinoma
Location: Stony Brook NY
Sponsor: Alexander Stessin

Sex: Female

Age: 18+

Code: NCT07122713

Recruiting

The Gut Microbiome and Immunotherapy Response in Solid Cancers

for
Cancer
Location: Galveston TX
Sponsor: The University of Texas Medical Branch, Galveston

Sex: All

Age: 35 - 70+

Code: NCT06050733

Recruiting

Digital Intervention for Symptom Management in Cancer and Opioid Sparing Using Virtual Reality (DISCOVR) Study

for
Cancer
Location: Washington D.C. DC
Sponsor: Medstar Health Research Institute

Sex: All

Age: 18+

Code: NCT07228377

Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for
Breast Neoplasms, Neoplasm Metastasis
Location: Westbrook ME, Lebanon NH, Summit NJ, Philadelphia PA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07174336

Phase 3, Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

for
Solid Tumor
Location: St. Petersburg FL, Dallas TX, San Antonio TX
Sponsor: Step Pharma, SAS

Sex: All

Age: 18+

Code: NCT06297525

Phase 1, Recruiting

The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services

for
Cardiac Conditions, Connective Tissue Diseases, Retinal Disease,
Location: Toronto
Sponsor: Unity Health Toronto

Sex: All

Age: 18+

Code: NCT06455384

Recruiting

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

for
Advanced Solid Tumors, Ewing Sarcoma,
Location: Boston MA, New York NY, Houston TX, Duarte CA,
Sponsor: SEED Therapeutics, Inc.

Sex: All

Age: 16+

Code: NCT07197554

Phase 1, Recruiting

Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Atlanta GA
Sponsor: Emory University

Sex: Female

Age: 18+

Code: NCT06534125

Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

for
Advanced Solid Tumors
Location: Fairfax VA, Huntersville NC, San Antonio TX
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07161414

Phase 1, Recruiting

Navigation Interventions for Patients With Breast Cancer and High-risk Social Determinants of Health

for
Breast Cancer, Cancer of Breast
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: Female

Age: 18+

Code: NCT07781800

Recruiting

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

for
Advanced Solid Tumors, Recurrent or Progressive Glioblastoma,
Location: Fairfax VA, Tampa FL, Houston TX, Duarte CA
Sponsor: Crossbow Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07779798

Phase 1, Recruiting

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

for
Liposarcoma, Prostate Cancer, Advanced Breast Cancer,
Location: New Haven CT, Trumbull CT, Grand Rapids MI,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT04557449

Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial